Advanced SearchNewsfeedFollowed Companies

Gilead's Competitors, Revenue, Number of Employees, Funding and Acquisitions

Gilead develops and commercializes therapeutics for the treatment of liver, cancer, inflammatory, respiratory and cardio... Read more

Based on data from Gilead's latest SEC filings

Annual Revenue

Based on data from Gilead's latest SEC filings

Employees

Daniel O’Day's photo - Chairman & CEO of Gilead

Chairman & CEO

Daniel O’Day

CEO Approval Rating

69/100

OVERVIEW

Founded:

1987

Headquarters:

Foster CityCalifornia

Status:

PublicNASDAQGILD

Industry Sector:

Specialty Pharmaceuticals

SIC Code:

2834NAICS listing »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Actelion a competitor of Gilead?

I don't know

Trending News for Gilead and Gilead's Competitors

February 24, 2020

Good Stock Invest

Novartis: accepted files for ofatumumab

02/24/2020 | 7:48 Novartis announces that the US FDA and the European Medicines Agency (EMA) have agr... See more »

February 24, 2020

MarketScreener

United Therapeutics : and DEKA Announce Additional FDA Clearance Related to the Unity Subcutaneous Delivery System for Remodulin�

(marketscreener.com) RESEARCH TRIANGLE PARK, N.C. and MANCHESTER, N.H., Feb. 24, 2020 /PRNewswire/ --... See more »

February 24, 2020

Seeking Alpha

Gilead JV application for CAR-T cancer therapy accepted in China

See more »

Competitive Analysis

TOP COMPETITORS OR ALTERNATIVES

AbbVie is perceived as one of Gilead's biggest rivals. AbbVie's headquarters is in North Chicago, Illinois, and was founded in 2013. AbbVie operates in the Pharmaceuticals industry. AbbVie generates 146% of Gilead's revenue.

Merck has been one of Gilead's top competitors. Merck is a Public company that was founded in 1891 in Kenilworth, New Jersey. Merck is in the Pharmaceuticals field. Compared to Gilead, Merck has 58,000 more employees.

Bristol Myers Squibb is Gilead's #3 rival. Bristol Myers Squibb was founded in New York, New York} in 1858. Bristol Myers Squibb operates in the Pharmaceuticals industry. Compared to Gilead, Bristol Myers Squibb generates $1.8B more revenue.

RANK

COMPANY

LEADERSHIP

CEO SCORE

EMPLOYEES

TOTAL FUNDING

REVENUE

Daniel O’Day

Chairman & CEO

- -
11,000
$86.3M
$22.4B
1

Richard A. Gonzalez

Chairman & CEO

71/100
78
$3.8B
$32.9B
2

Kenneth C. Frazier

Chairman & CEO

72/100
69,000
- -
$46B
3

Giovanni Caforio

Chairman & CEO

78/100
23,300
- -
$24.2B
4

Vasant Narasimhan

CEO

78/100
118,393
- -
$50.3B
5

CEO

- -
2,421
- -
$2.4B
6

Martine Rothblatt

Founder & CEO

66/100
860
$54M
$1.5B
7

Albert Bourla

CEO

67/100
92,400
- -
$53B
8

Alexander Hardy

CEO

69/100
14,717
$100M
$18.3B
9

Robert A. Bradway

Chairman & CEO

64/100
19,200
$19M
$23.4B
10

David A. Ricks

Chairman & CEO

71/100
38,680
- -
$22.3B
The top 10 competitors in Gilead's competitive set are AbbVie, Merck, Bristol Myers Squibb, Novartis, Actelion, United Therapeutics, Pfizer, Genentech, Amgen and Eli Lilly. Together they have raised over 4.0B between their estimated 396.2K employees. Gilead has 11,000 employees and is ranked 8th among it's top 10 competitors. The top 10 competitors average 35,459.

Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$22.4B

Gilead's revenue is the ranked 7th among it's top 10 competitors. The top 10 competitors average 27B. Over the last four quarters, Gilead's revenue has decreased by 3.3%. Specifically, in Q3 2019's revenue was $5.6B; in Q2 2019, it was $5.7B; in Q1 2019, it was $5.3B; in Q4 2018, Gilead's revenue was $5.8B.

Acquisitions

COMPANY ACQUIRED
ACQUISITION DATE
AMOUNT
DESCRIPTION
Cell Design Labs, Inc.

Dec 2017

Source »
$175M
Cell Design Labs focuses on developing CAR-T and T cell receptor therapies for the treatment of cancer.
Kite Pharma, Inc.

Aug 2017

Source »
$11.9B
Kite Pharma is a biotechnology company that discovers and develops cell-based immunotherapies for the treatment of cancer.
Nimbus Therapeutics, Inc.

Apr 2016

Source »
$1.2B
Nimbus Therapeutics designs and develops novel treatments for metabolic disease, cancer and immune-inflammatory disorders.
EpiTherapeutics ApS

May 2015

Source »
$65M
EpiTherapeutics is a biopharmaceutical firm that develops cancer drugs based on the research in epigenetics field.

-

-

Nov 2010

Source »
$225M
-

These are all the companies that Gilead has acquired. Gilead has acquired 5 companies and its latest acquisition was Cell Design Labs, Inc. in Dec 2017. Cell Design Labs focuses on developing CAR-T and T cell receptor therapies for the treatment of cancer.

Gilead Funding History

Since Gilead was founded in 1987, it has participated in 1 round of funding. In total Gilead has raised $86.2M. Gilead's funding round was on Jan 1992 for a total of $86.2M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

IPO
Jan 1992
$86.3M

Total Funding: $86.3M

Since Gilead was founded in 1987, it has participated in 1 round of funding. In total Gilead has raised $86.2M. Gilead's funding round was on Jan 1992 for a total of $86.2M

Investments

COMPANY

DESCRIPTION

AMOUNT

INVESTMENT DATE

ROUND

EXIT DATE

Kyverna Therapeutics is a pharmaceutical company that researches and develops novel therapeutics for the treatment of autoimmune diseases.
$25M
Jan 12, 2020
Series A
-
Tmunity is a biotherapeutics firm that develops and commercializes T cell-based immunotherapies for the treatment of cancer.
$75M
Oct 21, 2019
Series B
-
AlloVir develops and commercializes novel cell therapies for the treatment of cancer and lyme diseases.
$121.3M
May 07, 2019
Series B
-
Lyndra is a pharmaceutical company that develops and commercializes oral contraceptive therapy for the treatment of Alzheimer's disease.
$55.2M
Jan 10, 2019
Series B
-
Glympse Bio develops and manufactures activity sensors for monitoring cancer and infectious diseases.
$22M
Oct 08, 2018
Series A
-

These are all the companies that Gilead has invested in. Gilead has invested 5 companies and its latest investment was Cell Design Labs, Inc. in Dec 2017. Cell Design Labs focuses on developing CAR-T and T cell receptor therapies for the treatment of cancer.

Gilead News

February 24, 2020Seeking Alpha

Gilead JV application for CAR-T cancer therapy accepted in China

See more »
February 21, 2020PharmaLive

Gilead Loses 2nd Patent Invalidation Challenge

Gilead Sciences lost yet another challenge to the company's U.S. patent to Truvada for HIV prevention... See more »
February 19, 2020The Business Journals: San Francisco Business Times

Gilead poaches Bristol-Myers Squibb site head in continuing exec team remake

Gilead Sciences Inc. added to its cancer-fighting lineup under new CEO Daniel O'Day, hiring the head ... See more »
February 19, 2020The Pharma Letter

Gilead announces hire of former B-MS exec, and a promotion

US biotech major Gilead Sciences announced today that Michael Quigley has joined the company as senio... See more »
February 17, 2020DirectorsTalk Interviews

Gilead Sciences, Inc. - Consenus Indicates Potential 12.3% Upside

Gilead Sciences, Inc. found using ticker (GILD) have now 22 analysts in total covering the stock. The... See more »
February 15, 2020The Business Journals: San Francisco Business Times

This Peninsula giant wants to build a 'wellbeing center' for employees

Gilead Sciences Inc. hopes to convert a parking lots on its sprawling Foster City campus into a 60,83... See more »
February 14, 2020Silicon Valley Daily

Vineti Nabs $35 Million Series C

SAN FRANCISCO - Vineti, which operates a digital platform of record for personalized therapeutics, ha... See more »

Gilead Press Releases

May 15, 2019Business Wire

Kite to Present New Data From Leading Cell Therapy Portfolio at ASCO 2019

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced that ne... See more »
May 10, 2019PR Newswire

Judge rejects Gilead's Motion to Dismiss AIDS Litigation

CORPUS CHRISTI, Texas, May 10, 2019 /PRNewswire/ -- In a ruling issued earlier today, the Honorable J... See more »
March 29, 2019GlobeNewswire

GILEAD EN GALAPAGOS RAPPORTEREN MEEST RECENTE VEILIGHEIDSINFORMATIE VOOR FILGOTINIB IN REUMA

-- Gecombineerde tussentijdse data uit Fase 3 FINCH programma na 24 weken en lange termijn-data van F... See more »
February 12, 2019centralcharts

Gilead Announces Topline Data From Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that STELLAR-4, a Phase 3, randomized, double-bl... See more »
January 23, 2019PRWeb

Agency Mania Solutions Presents with Gilead Sciences and HP Inc. at ANA Advertising Financial Management Committee West Coast Chapter Meeting

Bruno Gralpois and Gilead Sciences' Keecia Scott share marketing operations tactics and a new approac... See more »
January 22, 2019StreetInsider

Gilead Sciences to Release Fourth Quarter and Full Year 2018 Financial Results on Monday, February 4, 2019

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2018 finan... See more »
January 10, 2019StreetInsider

Fish & Richardson Obtains Denial of Cert at U.S. Supreme Court for Gilead Sciences in Long-Running Patent Battle with Merck Over Hepatitis C Drugs

Fish & Richardson has obtained a denial of certiorari at the U.S. Supreme Court for client Gilead Sci... See more »

Gilead Videos

September 30, 2019Gilead Youtube Channel

"#SpreadFactsNotFear | Jessica Zyrie on Countering Trans Discrimination" on YOUTUBE

See more »
September 30, 2019Gilead Youtube Channel

"#SpreadFactsNotFear | Guillermo Chacon debate habla sobre el VIH y el envejecimiento" on YOUTUBE

See more »
September 30, 2019Gilead Youtube Channel

"#SpreadFactsNotFear | Guillermo Chacon Discusses HIV and Aging" on YOUTUBE

See more »
September 30, 2019Gilead Youtube Channel

"#SpreadFactsNotFear | Bruce Richman on How Dismantling HIV Stigma Gives Him Hope" on YOUTUBE

See more »
September 3, 2019Gilead Youtube Channel

"Gilead COMPASS Initiative" on YOUTUBE

See more »
July 30, 2019Gilead Youtube Channel

"Perspectives from CROI 2018 - Dr. Cissy Kityo Mutuluuza" on YOUTUBE

See more »
July 30, 2019Gilead Youtube Channel

"Doug Brooks' HIV Story" on YOUTUBE

See more »

Social Statistics

Headquarters

333 Lakeside Drive

Foster City, California94404

1-650-574-3000

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

Gilead develops and commercializes therapeutics for the treatment of liver, cancer, inflammatory, respiratory and cardiovascular diseases. Gilead was founded in 1987. Gilead's headquarters is located in Foster City, California, USA 94404. It has raise...

CEO

Gilead's Chairman & CEO, Daniel O’Day, currently has an approval rating of 69%. Gilead's primary competitors are AbbVie, Merck & Bristol Myers Squibb.

Website

gilead.com

Frequently Asked Questions about Gilead

  1. When was Gilead founded?

    Gilead was founded in 1987

  2. Who is Gilead's CEO?

    Gilead's CEO is Daniel O’Day

  3. How much revenue does Gilead generate?

    Gilead generates $22.4B in revenue

  4. How much funding does Gilead have?

    Gilead has historically raised $86.3M in funding

  5. Where is Gilead's headquarters?

    Gilead's headquarters is in Foster City California, USA

  1. How many employees does Gilead have?

    Gilead has 11,000 employees

  2. What sector does Gilead operate in?

    Gilead is in Specialty Pharmaceuticals

  3. Who are Gilead's competitors?

    Gilead's top competitors are AbbVie, Merck, Bristol Myers Squibb

  4. Who has Gilead invested in?

    Gilead's has invested in companies such as Kyverna Therapeutics, Tmunity, AlloVir
Stay up-to-date with the latest news on Gilead